Research Article
Research on the bonds of Hengrui Pharmaceutical Company
@INPROCEEDINGS{10.4108/eai.17-6-2022.2322864, author={Jiaxin Zheng}, title={Research on the bonds of Hengrui Pharmaceutical Company}, proceedings={Proceedings of the International Conference on Information Economy, Data Modeling and Cloud Computing, ICIDC 2022, 17-19 June 2022, Qingdao, China}, publisher={EAI}, proceedings_a={ICIDC}, year={2022}, month={10}, keywords={hengrui; epidemic; bond; yield; duration}, doi={10.4108/eai.17-6-2022.2322864} }- Jiaxin Zheng
Year: 2022
Research on the bonds of Hengrui Pharmaceutical Company
ICIDC
EAI
DOI: 10.4108/eai.17-6-2022.2322864
Abstract
After the outbreak of the epidemic, this paper selects Hengrui (Jiangsu Hengrui Co., Ltd.) medicine as the research object, makes a macroeconomic analysis of the industry, then analyzes the pharmaceutical industry, obtains the development trend of the industry, and puts forward investment strategy suggestions. This paper uses the basic data information of Hengrui pharmaceutical bonds, including yield, bond term, issuance date and cash flow in different months. At the same time, the strength of the pharmaceutical sector index is mainly due to the joint action of factors such as the recovery of profits in the pharmaceutical industry, the gradual weakening of the impact of resistance restriction, and the favorable overall policy in the first half of the year. Macaulay duration model and Fish Weil model are used to support the view of this paper. The strength of the pharmaceutical sector index is mainly due to the joint action of factors such as the recovery of profits in the pharmaceutical industry, the gradual weakening of the impact of drug prohibition orders, and the favorable overall policies in the first half of the year. This paper attempts to help investors have a sufficient understanding of pharmaceutical bonds.